Plain-English translation of NCT06467565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a chemotherapy combination called NALIRIFOX—made up of four different cancer-fighting drugs given together—in patients with pancreatic cancer that hasn't spread beyond the pancreas and hasn't been treated with surgery or other cancer drugs yet. The goal is to see if this medication can shrink the tumor enough to make it possible to remove surgically, and to learn how well patients tolerate the treatment.
Pancreatic cancer that is locally advanced (contained to the pancreas but too large or complex to remove immediately) is very difficult to treat. This medication is being tested because early results suggest it may be more effective at shrinking these tumors than standard treatments, potentially giving more patients the chance to have successful surgery.
You would receive the four-drug chemotherapy combination intravenously (through a vein) once every 2 weeks, with treatment organized into 4-week cycles. After completing the first 2 cycles, you would have imaging scans to see how well the treatment is working. If the tumor is responding, you would continue treatment every 2 weeks until you are ready for surgery, or for up to 24 weeks, after which you would switch to an oral maintenance medication. Throughout the trial, you would have regular blood tests and scans (approximately every 8 weeks initially, then every 12 weeks during maintenance) to monitor your response and any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~20 participants
Started
December 2023
Primary completion
December 2024
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rong K Jiang, MD
The First Affiliated Hospital with Nanjing Medical University